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Abstract Using RT-PCR we distinguished mRNAs for all 
known G-protein coupled serotonin receptors expressed in vari- 
ous rat and porcine blood vessels. Nearly all vessels expressed 
5HT1D m 5-HT2A, 5-HT2B, 5-HT4, and 5-HT 7 receptor mRNA to 
different extents. New splice variants of the porcine 5-I-11"4 recep- 
tor were observed. Similar PCR assays were performed with 
endothelial and smooth muscle cells from human pulmonary ar- 
tery, aorta, and with endothelial cells from human coronary ar- 
tery and umbilical vein. All endothelial cells expressed 5-HT~Dm 
5-HT2B, and 5-HT4 receptor mRNA, whereas in smooth muscle 
cells 5-HTIDt3, 5-HT2A, 5-HTT, and in some experiments 5-HT2B 
receptor mRNA were found. A model for the regulation of vascu- 
lar tone by different 5-HT receptors is proposed. 
Key words: Endothelium; Nitric oxide; 5-HT receptor; 
5-HT 4 receptor; Smooth muscle 
I. Introduction 
It has been established that serotonin stimulates both, con- 
traction and relaxation of blood vessels [1,2,3]. Extensive f- 
forts have been made to unravel the molecular identity of the 
serotonin receptors involved in the regulation of blood vessel 
tone and the biochemical mechanisms by which they exert heir 
functions. 
Thirteen different mammalian G-protein coupled 5-HT re- 
ceptor types have been identified by molecular cloning, which 
have been grouped into seven families [4]. The five 5-HT~ recep- 
tor subtypes, 5-HT1A to 5-HT1F , inhibit adenylate cyclase activ- 
ity after expression i mammalian cell lines (the former 5-HTlc 
receptor is now named 5-HT2c, the 5-HT~B receptor is the 
rodent analogue of the 5-HTma receptor found in other spe- 
cies). The three 5-HT2 receptor subtypes, 5-HT2A to 5-HT2c, 
stimulate the hydrolysis of phosphatidylinositol. 5-HT4, 5-HT6, 
and 5-HT 7 receptors enhance adenylate cyclase activity. No 
functional coupling has yet been described for the 5-HTs~aB 
receptor subtypes [5]. 5-HT 3 receptors, which are receptor- 
channel complexes, may also represent a heterogenous group 
[6]. 
Using organ bath experiments, it has previously been demon- 
strated that 5-HT2c-like and 5-HTl-like receptors induce vessel 
relaxation in an endothelium-dependent fashion [7-11]. Other 
5-HTl-like receptors were reported to trigger relaxation of 
blood vessels independent of the presence of an intact endothe- 
lium [12,13]. Smooth muscle contraction is induced independ- 
ently of the endothelium by activation of 5-HT2A receptors 
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[1,3]. In addition, 5-HT~-like receptors with a pharmacological 
profile resembling that of 5-HTJ5-HTIDJ5-HT1D~ receptors 
have been shown to induce smooth muscle contraction [14]. It 
is clear that serotonin regulates vasoconstriction a d vasorelax- 
ation in a complex way which involves the interaction of several 
serotonin receptor subtypes with conflicting functional effects. 
The rapid cloning of new 5-HT receptors has not been 
matched by the discovery of subtype-selective ligands. Quite 
often, receptor ligands that were considered to be selective for 
a given subtype turned out to have high affinity for one of the 
more recently discovered 5-HT receptors. In addition, the char- 
acterization of the receptor subtypes involved was hampered by 
species dependent receptor pharmacology for the functional 
assays. In the absence of highly specific receptor ligands, it has 
become much more difficult to characterize pharmacological 
responses as being mediated by a certain 5-HT receptor sub- 
type. 
Using RT-PCR we have identified the 5-HT receptor 
mRNAs expressed in whole blood vessels and in various endo- 
thelial and smooth muscle cells by amplification and sequenc- 
ing of their cDNAs. The function of most of these defined 
receptors in vascular cells is then discussed in the context of the 
numerous previous publications dealing with functional analy- 
ses. 
2. Materials and methods 
2.1. Oligonucleotides 
The following oligonucleotides (ON) were used as primers for RT- 
PCR with the respective accession umber and position of the PCR 
product in the coding sequence in brackets: rat 5-HT1A 005276, posi- 
tion 4-202) ON 1: GAT GTG TTC AGT TTT GGC CAG G, ON 2: 
GGA GCG CTC CAA GGC GAT GGC A; human 5-HT1A (M83181, 
position (-133)-197) ON 3: CCT GCT TGG GTC TCT GCA TTC 
C, ON 4: GGA GCG CTC CAA GGG GAT GGC A; rat 5-HT~B 
(M89954, position 98-325, also used for porcine tissue) ON 5: ACT 
ACA TTT ACC AGG ACT CCA T, ON 6: CAG TGA CCG TGT 
ACA TGG TGC; human 5-HTtD ~ (M75128, position 140-742) ON 7: 
CCT GGA AAG T(AC)C TGC TGG T, ON 8: CGG TC(CT) TGT 
TGG G(TC)G TCT GT; rat 5-HTjD (M89953, position 262-702) ON 
9: TCA TGC CCA TCA GCA T(CA)G CC, ON 10: CTT CCC 
(AG)TA GAG (TG)GA GGG TG; human 5-HT~D~ (M81589, position 
272-711) ON 11: TCA TGC CCA TCA GCA T(AC)G CC, ON 12: 
CTT CCC (AG)TA GAG (TG)GA GGG TG; human 5-HT~z (Z11166, 
position 134-629, also used for porcine tissue) ON 13: TGG CTA TTG 
GCA CCA CCA AGA A, ON 14: TTG GCC GCG TGG TAA ATC 
CG; rat/human 5-HT~F (L05596, position 138-503) ON 15: TGC 
(AG)AT (TC)AT TGT GAC (CT)CG GA, ON 16: C(GT)G CTA 
(TG)TT CCT TGG TGC CTC; rat 5-HT2A (M36966, position 336-600) 
ON 17: CAT CCT GTA TGG GTA CCG GT, ON 18: AAA GAC CTT 
CGA ATC ATC CTG; porcine 5-HT2A (position 349600 in rat se- 
quence) ON 19: TAC CGG TGG CCT TTG CCT AG, ON 18; human 
5-HT2A (M36966, position 560~837) ON 20: ACT CCA GAA CTA 
AGG CAT TT, ON 21: AGC TAA TTT GGC CCG TGT GCC; rat 
5-HT2B (X66842, position 349-571, also used for porcine tissue) ON 22: 
AGG CTA CAT GGC CCC TCC CAC T, ON 23: TAG GGA CTG 
GGA TGG CGA TG; human 5-HT2~ (X77307, position 404-835) ON 
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24: ACG TTC TCT TTT CAA CCG CA, ON 25: CCG GTG ACG 
AGC AAG GTG TT; rat 5-HT2c (M21410, position 567-917) ON 26: 
TAT CCC TGT GAT TGG ACT GAG, ON 27: GTT GAT AGC 
(CT)TG CAT GGT GC; human 5-HT2c (M81778, position 323-611) 
ON 28: CCC TGT CTC TCC TGG CAA TC, ON 29: TTG TTC ACG 
AAC ACC TTT TC; rat 5-HT4 degenerate cloning oligonucleotides 
(position 244-827) ON 30: GT(GC) CAG GAC ATC TGG TTC 
TA(TC) GG(CT) GA(GA) ATG TT, ON 31 : AA(AG) AA(GC) GGC 
GCC CAG CAG AAA CAG AAG CA(TG) CCC AT; rat 5-HT 4 
specific primers (position 346-743) ON 32: CTG GAT AGG TAT TAT 
GCC ATC T, ON 33: GTG CTG TGC TGG TCA GCT GTC T; ON 
32, ON 31 were used for porcine tissue and are positioned in the rat 
sequence 346-827; rat 5-HT 4 degenerate oligonucleotides for cloning 
the human 5-HT4 receptor (position 304-827) ON 34: CTA CTC ACC 
AC(ACG) GC(AC) TC(ACG) ATT TT, ON 31; human 5-HT 4 specific 
primers (length of PCR-product 397 bp) ON 35: CTG GAT AGG TAT 
TAC GCC ATC T, ON 36: GTG CTG TGC TGG TCA GCT GTC 
T; rat 5-HTsA m (L10072/L10073, position A306/B346-A662/B702) ON 
37: CTG GGC G(CA)C G(CT) T GGC AGC T, ON 38: TCC AGT 
A(CG)A C(AG)A AGA GCA CCA C; human 5-HTsA (X81482, posi- 
tion 306-662) ON 37, ON 38; rat  5 -HT  6 (L19656, position 135~,18) ON 
39: GCT GCT GAT CGT GCT CAT TTG CA, ON 40: CTG TCA 
TGC GCA GCT TGT AGC GCA; human 5-HT 6 (Z49119, length of 
PCR-product 200bp) ON 41: CTG CCC GCA AGC AGG CCG TGC 
A, ON 42: GTC ACA AAG AAC ATG CCC AGC; rat 5-HT7 (L19654, 
position 713-1044, also used for porcine tissue) ON 43: AGG ATT 
TTG GCT ACA CGA TC, ON 44: GAG GAA AAA CGG CAG CCA 
GCA; human 5-HT 7 (L21195, position 704-1035) ON 45: AGG ACT 
TTG GCT ATA CGA TT, ON 46: GAG GAA AAA TGG CAG CCA 
G; human yon Willebrand factor (X04385, position 2522-2859) ON 47: 
AGT GAA GAT TGG CTG CAA CAC T, ON 48: CAA AGT GAG 
TCT CAT CCT TCA T; human endothelial NO-synthase (M93718, 
position 1424-1992) ON 49: TTC CAT CAG GAG ATG GTC AAC 
TA, ON 50: GAG CAA AGG CGC AGA AGT GGG GGT A. 
Oligonucleotides were synthesized on an Applied Biosystems 380A syn- 
thesizer and purified by gel filtration through Sephadex G-25 columns 
(Boehringer). 
2.2. Tissues, cell culture, RNA-preparation a d RT-PCR 
RNA was isolated according to the guanidinium ethod [15]. Blood 
vessels were carefully isolated and cleaned of adhering parenchyma and 
connective tissue. The tissue was homogenized in RNA-buffer using a 
POLYTRON homogenizer. Human primary cells (pulmonary artery 
endothelial (HUPAEC) and smooth muscle cells (HUPASMC), aortic 
endothelial (HUAEC) and smooth muscle cells (HUASMC), coronary 
artery (HUCAEC) and umbilical vein endothelial cells (HUVEC)) and 
culture media were purchased from Clonetics (San Diego). Cells were 
grown according to the supplier's instructions and used for up to four 
passages. Cells (1×106) were washed twice with PBS, scraped off, spun 
for 15 s in a minifuge and dissolved in RNA-buffer. Residual DNA was 
digested with 10 U DNAse (Boehringer) per 10 gtg RNA for 20 min at 
37°C. For the RT-PCR, 1 gtg of each RNA was reverse transcribed in
a final volume of 20/zl using M-MLV reverse transcriptase (BRL) in 
PCR-Buffer (Boehringer), 200/zM dNTP (Cetus), 10 mM DTT, 5/tM 
hexanucleotides (Pharmacia), and 40 U RNasin (Promega) for 1 h at 
37°C. 38 PCR cycles (55°C for 30 s, 72°C for 1 min, 94°C for 30 s) were 
performed in a final volume of 50/A with 10% of the reverse transcrip- 
tion (RT) mixture, 10 pmol of each primer, 1 U Taq-DNA-polymerase 
(Boehringer), 250/~M dNTP and 2/~Ci [ct-nP]dCTE The 32p-labeled 
PCR-products were separated on 4% agarose gels (NuSieve, FML). 
The gels were dried and exposed to X-ray films. 
2.3. Direct PCR-sequencing 
1 H1 of all PCR-products was re-amplified in a second reaction, 
separated on a 4% agarose gel and the bands were extracted with the 
QUIAEXgel extraction kit (Quiagen). Approximately 100 ng DNA was 
used as template for the direct PCR-sequencing reaction. Dideoxy se- 
quencing of both strands was performed using a Hot Tub DNA se- 
quencing system (Amersham) or an automated sequencer (Applied 
Biosystems 373A). The DNASIS program (Hitachi) was used for se- 
quence analyses. 
2.4. 5-HT4 receptor cloning 
A set of degenerate primers was designed based on the published 
5-HT4 receptor amino acid sequence [16]. ON-30 (aa82-aa92) was lo- 
cated in transmembrane domain III, ON 31 in transmembrane region 
VI (aa265-aa275). PCR reactions were performed using rat colliculi 
cDNA under standard conditions except hat the annealing tempera- 
ture was lowered to 50°C. The PCR product was sequenced as de- 
scribed above. From the resulting nucleotide sequence, the specific 
primers ON 32 and ON 33 for the rat 5-HT 4 receptor were designed. 
Human and porcine 5-HT4 receptor sequences were obtained by per- 
forming PCR with the primers ON 34lON 31 and ON 32/ON 31, 
respectively, using human or porcine striatum cDNA as template. For 
the analysis of receptor expression, ON 32 and ON 31 were used for 
pig, ON 35 and ON 36 for human RNAs. 
To clone the porcine 5-HT 4 splice variants, RT-PCR products from 
porcine coronary artery RNA were further amplified using kinased ON 
32 and ON 31. Overhangs were filled with 2 U Klenow enzyme in 6 mM 
MgCl2 for 20 min at 37°C. Products were isolated by gel electrophore- 
sis, ligated into pBSKSII and sequenced using standard methods. 
3. Results 
3.1. Analysis of serotonin receptor expression in blood vessels by 
RT-PCR 
Based on published serotonin receptor sequences we have 
designed PCR primers which distinguish all known G-protein 
coupled serotonin receptors. The functionality and specificity 
of the primer pairs were controlled by RT-PCRs with RNA 
from tissues known to express the receptors or, in cases where 
introns are absent, with genomic DNA (data not shown). PCR 
primer pairs were either species-specific or, where possible, 
selected such that they worked with cDNAs from several spe- 
cies (rat, mouse and human). All PCR products have been 
characterized by direct DNA sequencing. 
3.2. Rat blood vessels 
Using RT-PCR we analyzed mRNAs for the serotonin re- 
ceptor subtypes expressed in various rat blood vessels (Fig. 1). 
Contamination with genomic DNA was excluded in all RNA 
preparations by performing the same RT-PCR procedure with- 
out adding reverse transcriptase (Figs. 1 and 3). Four different 
5-HT receptor mRNAs,  5-HT~, 5-HTeA, 5-HT2m and 5-HT 7 
were found (Fig. 1A). The relative abundance of these mRNAs 
varied for different vessel types. None of the other 5-HT recep- 
tor types analyzed (5-HT1A, 5-HT1D, 5-HT1F, 5-HT2o 5-HTsA, 
Table 1 
Percent homology of porcine 5-HT receptor partial nucleotide sequences with the rat and human homologs 
Porcine 5-HTIDp 5-HT~E 5-HT2A 5-HT2B 5-HT4 5-HT7 
(Z47984) ~ (Z48151)a (Z48152) a (Z48174) a (4A: Z48175) ~ (Z48177) a 
(4B : Z48176) a
Human 87.0 99.8 96.8 95.2 88.7 89.5 
(70.8~D~) b (Z48150)" 
Rat 84.9 - 88.0 87.1 85.4 88.4 
(71.21D) b (Z,48153) a 
EMBL data library accession umber. 
b Sequence homology to the closely related 5-HT~D~ID receptor. 
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Fig. 1. Agarose gel electrophoresis of PCR-amplified products derived from cDNA of various rat (A) and porcine (B) blood vessels. As control for 
the absence of DNA contaminations, all RT-PCRs were performed with or without reverse transcriptase (+ or - RT) added to the cDNA synthesis 
reaction. (A) For rat tissues the following primers were used (size of the PCR-products inbrackets): 5-HT~B: ON5/ON6 (227 bp), 5-HT2A: ON17/ON18 
(265 bp), 5-HT2B: ON22/ON23 (222 bp), 5-HT7:ON43/ON44 (332 bp). (B) For porcine vessels: 5-HTm: ON5/ON6 (227 bp), 5-HT2A: ON19/ON18 
(252 bp), 5-HT2B: ON22123 (222 bp), 5-HT7:ON43144 (332 bp). (C) Porcine 5-HT 4 receptor primers ON321ON31 gave rise to PCR-products of 440 
bp and 482 bp, respectively. RNA was isolated from coronary artery (lane 1), cerebral rtery (lane 2), pulmonary artery (lane 3), cerebral vein (lane 
4). Lane 5 shows 5-HT 4 receptor mRNA expression i  porcine colliculi as positive control. 
5-HT5a, and 5-HT6) was expressed in vascular tissue (data not 
shown). 
No nucleotide sequence had become available for the phar- 
macologically well-defined 5-HT4 receptor. Using degenerate 
oligonucleotides which were based on the recently described rat 
protein sequence [16] we amplified and cloned a partial 5-HT 4 
receptor cDNA sequence from rat colliculi. Subsequently, the 
corresponding cDNAs were also amplified from human and 
porcine striatum (Fig. 2, Table 1). In RT-PCR experiments no 
5-HT 4 receptor mRNA was found in rat blood vessels (data not 
shown). 
3.3. Porcine blood vessels 
Multiple sets of PCR primers were designed based on the 
known mouse, rat and human sequences. Amplification of 
cDNAs from porcine pulmonary artery allowed the elucidation 
of partial sequences for the porcine homologues of those 5-HT 
receptors which we found to be expressed in rat blood vessels 
(5-HT~Dp, 5-HT2A, 5-HT2B and 5-HT7). Since only human, no 
rodent, 5-HT1E receptor sequences had been described, we also 
cloned and sequenced PCR products that were derived from 
porcine genomic DNA with primers specific for the human 
5-HTIE receptor. All porcine sequences showed very high ho- 
mology to their rat and human equivalents (Table 1). 
RT-PCRs with RNA isolated from various porcine blood 
vessels revealed that the same set of serotonin receptors that 
was observed in the rat was also present in the pig (Fig. 1B). 
No expression was detectable for the 5-HT~E receptor mRNA 
(data not shown). The relative abundance of all mRNAs found 
was variable. While we did not find 5-HT4 receptor mRNA in 
rat blood vessels, it was clearly expressed in vascular tissues 
from the pig (Fig. 1C). Moreover, all porcine blood vessels 
contained two splice variants of the 5-HT 4 receptor (called 
5-HT4A and 5-HT4B). The larger 482 bp PCR product represent- 
ing the 5-HT4B splice form was not present in porcine colliculi 
(Fig. 1C, lane 5), human striatum or human endothelial cells 
(Fig. 3B). Subcloning, sequencing and alignment to the rat and 
human 5-HT 4 receptor sequences revealed that the 5-HT4B 
isoform harbors an insertion of 14 amino acids compared to the 
porcine 5-HT4A receptor. Fig. 2 shows an alignment of the 
partial porcine, human and rat 5-HT 4 receptor sequences in- 
cluding the new 5-HT4B splice-variant found in porcine blood 
vessels. 
3.4. 5-HTreceptor expression in primary human endothelial and 
smooth muscle cells 
To localize the cellular distribution.6f the 5-HT receptors 
found in whole blood vessels, we used primary cultures of 
human endothelial nd smooth muscle cells from several differ- 
ent vessels. RT-PCRs were performed with RNAs isolated 
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PIG 5-HT4A 
PIG 5-HT4B 
TM I I I  TN IV 
• 104 114 124 134 144 154 164 170 
VRTSLDVLLT TASIFHLCCI SLDRYYAICC QPLVYRNKHT PLRIALHLGG Ct, NIPMFISF LPIMOGWNNI GIVDV . . . . . . . . . . . . . .  I 
. . . . . . * ******  . * ********  .wwww.www. *****TWWW. ****ww. . **  **IWL . . . . . . . . . . . . . .  w 
**  **********  ***V*VL*A* **A**VL***  **********  **T*L . . . . . . . . . . . . . .  * 
**  **********  ***V*VL*A* **A**VL***  **********  **T*LERTSK PRLGQDLHV* 
¢ 190 TNV 200 210 • 230 240 • 259 
RAT 5-HT4 EKRKFNHNSN $TFCVFHVNK PYAITCSVVA FYIPFLLNVL AYYRIYVTAK EHAQQIQHLQ RAGATSESRP OTADQHSTHR HRTETKAAK 
HUR 5-HT4 ******O***  **Y*******  **********  **********  **********  ***H******  ****S*****  *S********  *****  
PIG 5-HT4A *****HQ***  **Y* I *****  **********  **********  ** l , l * ******  ***H******  ****PA*G** PS********  *********  
PIG 5-HT48 *****HQ***  **ywIwwww* **********  **********  **Wwwwwww* ***HW*****  ****PAWGR* PS wwwwwww* *********  
Fig. 2. Alignment of partial rat, human and porcine 5-HT 4 receptor sequences. Amino acid identities are illustrated by asterisks. Bars represent the 
putative membrane spanning regions. Recognition moti~ for protein kinase C I ,  casein kinase II • and N-glycosylation * are indicated. The nucleic 
acid sequences have been deposited at the EMBL data library. For accession umbers ee Table 1. 
f rom these cell cul tures as descr ibed above.  P r imers  were de- 
s igned based on pub l i shed human receptor  sequences.  We have 
depos i ted a part ia l  human 5 -HT  6 receptor  sequence in the 
EMBO data  base (accession umber  Z49119).  
In cu l tured endothel ia l  cells f rom pu lmonary  and  coronary  
artery, umbi l ica l  vein and  aorta,  we found  express ion o f  5- 
HT1D p and  5-HT2B receptor  mRNAs  (Fig. 3A). Fur thermore ,  
there was weak  express ion o f  5-HT4 receptor  mRNA in these 
cells (Fig. 3B). A l though this express ion was low compared  to 
the abundance  o f  the mRNA in human s t r ia tum (Fig. 3B, lane 
C), it was clearly detectable while it was total ly miss ing  in 
smooth  musc le  cells. In  RNA isolated f rom one preparat ion  o f  
umbi l ica l  vein endothel ia l  cells, minute  amounts  o f  5 -HT  7 re- 
ceptor  mRNA were also detected (Fig. 3A). Smooth  musc le  
cells expressed a mixture  o f  5-HT1D p, 5-HT2A, 5-HT7, and  in 
some preparat ions  mal l  amounts  o f  5-HT2B receptor  mRNA 
(Fig. 3C). To ensure  that  the smooth  musc le  cul tures were not  
c ross -contaminated  with endothel ia l  cells, we per fo rmed RT- 
PCRs  with pr imers  for  yon  Wi l lebrand factor  and  endothel ia l  
nitr ic oxide synthase,  specific markers  for endothel ia l  cells 
[17,18] (Fig. 3D). These cul tures did not  conta in  contaminat ing  
endothel ia l  cells since both  RNAs  were not  detectable.  Con-  
versely, the endothel ia l  cell cu l tures shou ld  not  be signif icantly 
contaminated  with smooth  musc le  cells, since they do not  con-  
ta in 5-HT2A receptor  mRNA,  wh ich  we found  to be expressed 
in smooth  musc le  cells. 
Table 2 represents  a summary  o f  all mRNA express ion data.  
4. Discussion 
The  molecu lar  analys is  o f  5 -HT  receptor  mRNA express ion 
in vascu lar  t issues revealed that  on ly  five o f  the 13 known 
G-prote in  coupled 5 -HT  receptor  mRNAs  are expressed in 
b lood vessels (5-HT1Dp, 5-HT2A, 5-HT2B, 5-HT4 and  5-HT7). In 
agreement  with this, 5 -HTm~ mRNA had  prev ious ly  been 
found  in bov ine and  human cerebral  arteries [19]. 5-HT2A recep- 
tor  mRNA was shown to be expressed in rat  aort ic smooth  
musc le  cells [20] and  5 -HT  7 mRNA in human coronary  artery 
[21]. No  express ion in b lood vessels had  before been shown for 
the 5-HT2B and  5-HT4 receptor  mRNAs .  
In addit ion,  5 -HT  receptor  mRNA express ion in p r imary  
human endothel ia l  and  smooth  musc le  cells was invest igated.  
The  same set o f  receptors  that  was  observed in rat  and  porc ine 
vessels was  also found  in these cells. The  use o f  p r imary  cells 
shou ld  min imize  the risk that  receptors  express ion changes  as 
a consequence  o f  ma inta in ing  cells in culture for  extended peri- 
ods o f  t ime. In whole  human vessels, for  instance the internal  
carot id  and  midd le  men ingea l  artery, we also found  the same 
Table 2 
Serotonin receptor mRNAs  expressed in rat and porcine blood vessels and human endothelial or smooth muscle cell cultures 
Receptor type 5-HT 1A 1B/Dfl 1D/D~ 1E 1F 2A 2B 2C 4 5A/B 6 7 
Rat aorta - + - n.d. - +++ ++ . . . .  + 
renal artery - ++ - n.d. - +++ +++ . . . .  + 
vena cava - +++ - n.d. - ++ ++ . . . .  +++ 
portal vein - +++ - n.d. - + . . . . .  + 
femoral vein - +++ - n.d. - + ++ . . . .  ++ 
jugular vein - + - n.d. - ++ +++ . . . . .  
Pig pulmonary artery n.d. + n.d. - n.d. +++ ++ n.d. + n.d. n.d. ++ 
coronary artery n.d, ++ n.d. - n.d. +++ ++ n.d. +++ n.d. n.d. ++ 
cerebral artery n.d, +++ n.d. - n.d. + ++ n.d. ++ n.d. n.d. ++ 
cerebral vein n.d. +++ n.d. - n.d. - + n.d. ++ n.d. n.d. ++ 
Human HUVEC - +++ . . . .  +++ - + - - + 
CAEC - +++ . . . .  + - + - - - 
PAEC - +++ . . . .  +++ - + - - - 
AEC - +++ . . . .  +++ - + - - - 
PASMC - ++ - - - +++ + . . . .  ++ 
ASMC - ++ - - - +++ + . . . .  +++ 
A semiquantitative evaluation of receptor mRNA levels (+, ++, +++) is based on a comparison of  PCR signal densities. Receptors are marked -
when no PCR signals were detected and n.d. when not determined. 
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Fig. 3. Agarose gel electrophoresis of PCR-amplified products derived from cDNA of primary cultures of various human endothelial cells (HUVEC, 
human umbilical vein endothelial cells; CAEC, coronary artery endothelial cells; PAEC, pulmonary artery endothelial cells; AEC, aortic endothelial 
cells) and smooth muscle cells (ASMC, aortic smooth muscle cells; PASMC, pulmonary artery smooth muscle cells). As control for the absence of 
DNA contaminations, all RT-PCRs were performed with or without reverse transcriptase (+or - RT) added to the cDNA synthesis reaction. (A) 
For human primary endothelial cells the following primers were used (respective size of the PCR-product in brackets): 5-HT~D~ ON7/ON8 (601 bp), 
5-HTzA ON20/21 (281 bp), 5-HT2B ON24/ON25 (432 bp), 5-HT70N45/ON46 (332 bp). Occasionally, the 5-HT~D~ primers used produced additional 
minor bands. DNA sequencing revealed that those were unrelated to the receptor, epresenting a type of artifact often seen in PCR experiments. 
(B) cDNA of human primary endothelial nd smooth muscle cells was amplified with the human 5-HT4 receptor primer-pair ON35/ON36 (397 bp). 
(C) For human primary smooth muscle cells the same human primers were used as in (A). (D) To test he purity of the cell cultures, cDNAs of human 
primary endothelial (EC) and smooth muscle cells (SMC) were analyzed for expression of the endothelial nitric oxide synthase (eNOS) using the 
primers ON49/ON50 (610 bp), and von Willebrand factor using the primers ON47/48 (390 bp). 
receptor subtypes expressed, which is in agreement with the 
data obtained using cultured human cells (unpublished). The 
cellular distribution of receptor expression may be confirmed 
by in situ hybridization techniques. 
Fig. 4 schematically summarizes the results of our study and 
combines them with previously published information about 
physiological responses and second messenger systems acti- 
vated by 5-HT receptors [3]. It can be concluded that activation 
of 5-HTzB receptors expressed on the endothelium relaxes the 
vessels. The pharmacological profile of the 5-HTEB receptor fits 
best to the endothelial receptor, which has been classified as an 
'atypical 5-HT' [3], 5-HTEc [11], or 5-HTzc-like receptor [10]. 
The latter publication shows that the endothelium-dependent 
relaxation of the pulmonary artery can be blocked by L-argin- 
ine, indicating that activation of the 5-HT2B receptor stimulates 
nitric oxide release, which elicits a strong vasorelaxant activity 
[22] through activation of soluble guanylate cyclase [23]. Previ- 
ously, we have shown that cloned 5-HTzB receptors activate 
calcium-dependent chloride channels when expressed in Xen- 
opus oocytes [24] and stimulate phosphoinositol hydrolysis in 
HEK 293 cells [25]. Therefore, we assume that NO is released 
from endothelial cells after the activation of the calcium-calm- 
odulin-dependent endothelial NO synthase. 
The other receptor mRNA found in relatively large quanti- 
ties in endothelial cells encodes the 5-HTmp receptor. 5-HT,- 
like receptors mediating endothelium-dependent relaxation 
with pharmacological properties most closely related to those 
of 5-HT~D receptors were first described in the coronary artery 
[26,8]. Although 5-HTloB receptors are expressed in these cells, 
it should be noted, that the pharmacology ofthis relaxation was 
similar but not identical to that of the cloned 5-HT~D~ or 5- 
HT~Dp receptors. Based on experiments performed with the 
cloned heterologously expressed 5-HT~Dp receptors [27] and 
with human endothelial cells from the umbilical vein [28], the 
5-HT1D~ receptor inhibits cAMP formation. The endothelium 
dependent relaxation had previously been shown to be sensitive 
to pertussis toxin [29], which is in agreement with a G~-protein 
mediated inhibition of adenylate cyclase. Therefore, it can be 
concluded that the 5-HTmp receptor contributes to vessel relax- 
ation. It remains to be determined whether an interaction be- 
tween several 5-HT receptor subtypes (f.i. 5-HT,D~ and 5-HTzB 
receptors) is responsible for the somewhat unusual pharmacol- 
ogy of this relaxing response. The available pharmacological 
data do not exclude such an interaction since the pharmacology 
of 5-HT1Dp and 5-HTzB receptors i  similar [30]. 
5-HT 4 receptors are potentially expressed on endothelial cells 
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Fig. 4. Schematic model of vascular serotonin receptors. 
based on the presence of small amounts of their mRNA. The 
positive coupling of this receptor type to adenylate cyclase 
observed in other tissues [31] renders it possible that it counter- 
acts the effects of 5-HTIDp receptors in endothelial cells. Inter- 
esting are the striking differences in receptor mRNA levels and 
splice forms between rat, pig and human. Further research is 
required before the functional role of this receptor and its splice 
forms can be discussed. 
A strong constrictor activity in blood vessels is exerted by 
5-HT2A receptors located on smooth muscle cells. Our PCR 
analysis is in agreement with multiple reports in the literature 
[3]. Activation of 5-HT2A receptors in smooth muscle cells trig- 
gers intracellular calcium release after stimulating phosphatidy- 
linositol hydrolysis [32]. The functional role of calcium in mus- 
cle contraction is well documented [33]. 
It has previously been assumed that an additional contractile 
response to serotonin may be mediated by the functional corre- 
late of one of the central 5-HT1D receptors [34,3]. Kaumann et 
al. [14] came to the conclusion that this endothelium independ- 
ent response in porcine coronary arteries displays 5-HT~Dp re- 
ceptor pharmacology. This is confirmed by our finding that the 
receptor subtype is indeed expressed in vascular smooth muscle 
cells. In agreement with this, it was shown that these 5-HTx-like 
receptors link to pertussis toxin-sensitive inhibition of cAMP 
accumulation and increases in intracellular Ca 2+ in smooth 
muscle cells from bovine basilar artery [35]. 
Small amounts of 5-HTzB mRNA were present in smooth 
muscle cells isolated from human pulmonary artery and aorta. 
This receptor elicits strong contractile responses of rat stomach 
fundus smooth muscle [36]. A role in vascular smooth muscle 
cells has not yet been found. We also detected mRNA for 5-HT7 
receptors in smooth muscle cells. 5-HTt-like receptors mediat- 
ing direct vasorelaxation i  the absence of endothelium have 
been described in several blood vessels from various species [3]. 
The pharmacology of these responses is consistent with the 
conclusion that they are mediated by 5-HT 7 receptors. Heterol- 
ogously expressed 5-HT 7 receptors were shown to stimulate 
adenylate cyclase activity [22]. An increase of cAMP in smooth 
muscle cells inhibits myosin light chain kinase, which would 
result in direct relaxation [37]. 
These data facilitate the interpretation of the many func- 
tional organ bath experiments described in the literature and 
provide a basis for the resolution of questions uch as the 
unusual pharmacological properties of the endothelium de- 
pendent 5-HTID~ relaxation. 
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